BACKGROUND Oxygen (O2) treatment has been a cornerstone in the treatment of patients with myocardial infarction. Recent studies, however, state that supplemental O2 therapy may have no effect or harmful effects in these patients. The aim of this study was thus to evaluate the effect of O2 therapy in patients with ST Elevation Myocardial Infarction (STEMI) based on the culprit vessel; Left Anterior Descending Artery (LAD) or Non-LAD. METHODS This was a two-center, investigator-initiated, single-blind, parallel-group, randomized controlled trial at the Skåne university hospital, Sweden. A simple computer-generated randomization was used. Patients were either randomized to standard care with O2 therapy (10 l/min) or air until the end of the primary percutaneous coronary intervention. The patients underwent a Cardiac Magnetic Resonance Imaging (CMRI) days 2-6. The main outcome measures were Myocardium at Risk (MaR), Infarct Size (IS) and Myocardial Salvage Index (MSI) as measured by CMRI, and median high-sensitive troponin T (hs-cTnT). RESULTS A total of 229 patients were assessed for eligibility, and 160 of them were randomized to the oxygen or air arm. Because of primarily technical problems with the CMRI, 95 patients were included in the final analyses; 46 in the oxygen arm and 49 in the air arm. There were no significant differences between patients with LAD and Non-LAD as culprit vessel with regard to their allocation (oxygen or air) with regards to MSI, MaR, IS and hs-cTnT. CONCLUSION The results indicate that the location of the culprit vessel has probably no effect on the role of supplemental oxygen therapy in STEMI patients. TRIAL REGISTRATION Swedish Medical Products Agency (EudraCT No. 2011-001452-11) and ClinicalTrials.gov Identifier (NCT01423929).

中文翻译：

---

基于罪犯血管的ST抬高型心肌梗死患者的氧气治疗：来自随机对照SOCCER试验的结果。

背景技术氧气（O 2）治疗已经成为治疗心肌梗塞患者的基石。但是，最近的研究表明，补充氧气治疗对这些患者可能没有作用或有害作用。因此，本研究的目的是基于罪魁祸首评估O2治疗对ST抬高型心肌梗死（STEMI）患者的疗效。左前降支动脉（LAD）或非LAD。方法这是一项由研究人员发起，由单中心，双盲，平行分组，随机对照的两中心试验，在瑞典斯科讷大学医院进行。使用简单的计算机生成的随机化方法。患者被随机分配到接受O2治疗（10升/分钟）或空气的标准护理，直到初次经皮冠状动脉介入治疗结束。患者在第2-6天接受了心脏磁共振成像（CMRI）。主要结果指标是通过CMRI测量的处于危险中的心肌（MaR），梗塞面积（IS）和心肌挽救指数（MSI）以及中度高敏感肌钙蛋白T（hs-cTnT）。结果总共评估了229例患者的资格，其中160例被随机分配到氧气或空气臂。由于CMRI的主要技术问题，最终分析包括95例患者。在氧气臂中为46，在空气臂中为49。LAD和非LAD罪犯血管在MSI，MaR，IS和hs-cTnT分配方面（氧气或空气）没有显着差异。结论结果表明，罪犯血管的位置可能对STEMI患者补充氧疗的作用没有影响。试用注册瑞典医疗产品管理局（EudraCT No. 2011-001452-11）和ClinicalTrials.gov标识符（NCT01423929）。